ClinicalTrials.gov
ClinicalTrials.gov Menu

Topoisomerase II Alpha Gene Amplification and Protein Overexpression Predicting Efficacy of Epirubicin (TOP)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00162812
Recruitment Status : Terminated (Low accrual rate)
First Posted : September 13, 2005
Last Update Posted : July 18, 2008
Sponsor:
Collaborators:
Gustave Roussy, Cancer Campus, Grand Paris
Centre Paul Strauss
Centre Hospitalier du Luxembourg
Clinique Louis Cathy - Baudour - Belgium
HIS - Site Etterbeek - Ixelles - Belgium
Clinique Saint Pierre - Ottignies -Belgium
Clinique Ste Elisabeth - Namur - Belgium
University Hospital of Crete
Feculdade de Medicina da Universidade de Sao Paulo - Brasil
Information provided by:
Jules Bordet Institute

No Study Results Posted on ClinicalTrials.gov for this Study
  Recruitment Status : Terminated
  Estimated Primary Completion Date : December 2008
  Estimated Study Completion Date : April 2009